Department of Medicine, University of Otago, Dunedin, New Zealand.
Eur J Clin Pharmacol. 2014 Oct;70(10):1221-6. doi: 10.1007/s00228-014-1733-7. Epub 2014 Aug 20.
Dose modification in renal impairment has traditionally been based on changes in estimated glomerular filtration rate (eGFR; estimated by creatinine clearance). However, many drugs are eliminated by tubular anionic and cationic transport where changes in eGFR may not necessarily reflect changes in tubular function. This study investigated the relationship between GFR and renal tubular function with reference to drug handling by using accepted drug probes.
Three drug probes, (51)Cr-EDTA, fluconazole, and pindolol, were administered to patients who had varying degrees of renal impairment. Blood sampling, assays, and a pharmacokinetic analysis were performed for all drug probes and endogenous urate. Measured GFR ((51)Cr-EDTA clearance; mGFR) was compared to tubular anionic transport (urate clearance), tubular reabsorption (fluconazole clearance), and tubular cationic transport (S-pindolol clearance).
A moderately strong association was demonstrated between the measured isotopic GFR and creatinine clearance (R(2) = 0.78). A moderate positive correlation was found between mGFR and proximal tubular anion transport and reabsorption (R(2) = 0.40-0.44, p < 0.0001). In contrast, cationic secretion correlated poorly with mGFR (R(2) = 0.11, p = 0.036).
Given that drug dosing schedules utilise eGFR values as the basis for modifying drug dosing, our results would suggest that a recommendation of a dose reduction according to eGFR alone should be treated with caution.
传统上,肾功能损害时的剂量调整是基于估计肾小球滤过率(eGFR;通过肌酐清除率估计)的变化。然而,许多药物通过肾小管阴离子和阳离子转运系统消除,而 eGFR 的变化不一定反映肾小管功能的变化。本研究使用公认的药物探针研究了 GFR 与肾小管功能之间的关系,以及与药物处理相关的关系。
将三种药物探针(51)Cr-EDTA、氟康唑和吲哚洛尔给予具有不同程度肾功能损害的患者。对所有药物探针和内源性尿酸进行了血样采集、检测和药代动力学分析。测定的肾小球滤过率((51)Cr-EDTA 清除率;mGFR)与肾小管阴离子转运(尿酸清除率)、肾小管重吸收(氟康唑清除率)和肾小管阳离子转运(S-吲哚洛尔清除率)进行比较。
(51)Cr-EDTA 同位素肾小球滤过率与肌酐清除率之间显示出中度强相关性(R(2)= 0.78)。mGFR 与近端肾小管阴离子转运和重吸收之间存在中度正相关(R(2)= 0.40-0.44,p < 0.0001)。相比之下,阳离子分泌与 mGFR 相关性较差(R(2)= 0.11,p = 0.036)。
鉴于药物剂量方案将 eGFR 值用作调整药物剂量的基础,我们的结果表明,仅根据 eGFR 建议减少剂量应谨慎对待。